Stacked logo.png
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease
20 mars 2024 20h05 HE | Sosei Group Corporation
HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei...
Stacked logo.png
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
20 mars 2024 20h01 HE | Sosei Group Corporation
GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights follows change in immunology research strategy...
Biora-tm_rgb.jpg
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
26 févr. 2024 08h00 HE | Biora Therapeutics, Inc.
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.
Biora-tm_rgb.jpg
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
08 févr. 2024 08h00 HE | Biora Therapeutics, Inc.
Dr. Ariella Kelman to participate in panel titled "The Next Evolutionary Steps in Addressing IBD" on Feb 28, 2024.
ABIVAX_Logo-RGB.png
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
02 févr. 2024 02h30 HE | Abivax
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December...
ABIVAX_Logo-RGB.png
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
24 janv. 2024 02h30 HE | Abivax
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS,...
Biora-tm_rgb.jpg
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
08 janv. 2024 08h00 HE | Biora Therapeutics, Inc.
SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue
Biora-tm_rgb.jpg
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
19 déc. 2023 08h00 HE | Biora Therapeutics, Inc.
Biora's latest patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract.
Organovo Logo (2 Color Med-Res-082117).png
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
06 déc. 2023 08h05 HE | Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Synlogic_Logo_Blue.png
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
07 nov. 2023 07h00 HE | Synlogic, Inc.
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...